Expression analysis of 11 TAAs in tumor samples confirmed that HNRPL, WHSC2, SART3, CypB, PTHrP, and UBE2V were expressed in most tumor cells, validating their immunogenicity, while pre-existing IgG responses in patient plasma further supported their potential for immune enhancement. The gene discussed is UBE2V1; the disease is neoplasm.